Molecular Imaging — MCQs

Q: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?

Treatment-induced necrosis with favorable prognosis. ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.

Q: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?

Well-differentiated slow-growing tumor. ***Well-differentiated slow-growing tumor*** - High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors. - Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate. *High grade aggressive tumor* - Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy. - These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**. *Necrotic tumor with inflammation* - **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake. - **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity. *False positive DOTATATE scan* - Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context. - A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.

Q: A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?

Both primary and nodal metastasis. ***Both primary and nodal metastasis*** - In lung cancer staging, a **Standardized Uptake Value (SUVmax)** greater than 2.5 in mediastinal lymph nodes is highly suspicious for **metastatic involvement**. - The node's SUVmax of 4.2 relative to the primary tumor's high uptake (8.5) strongly indicates **metabolically active disease** at both the primary and nodal sites. *Primary tumor with false positive node* - **False positives** on PET often occur due to granulomatous disease or infection, but an SUVmax of 4.2 in a known cancer context is more likely **metastatic**. - Without history of **sarcoidosis** or active infection, the metabolic activity in the lymphatic basin of the primary tumor is considered malignant until proven otherwise. *Dual primary malignancies* - Two separate primary malignancies would typically involve different anatomical sites or different **histological features**, rather than a primary and its draining node. - The presence of a mediastinal node in a patient with a known lung mass is the classic presentation of **regional spread** (N staging), not a second primary site. *Primary tumor only, node is inflammatory* - While inflammation can cause **FDG avidity**, an SUVmax of 4.2 is significantly high and less typical for purely reactive or **incidental inflammatory** nodes. - Relying on an inflammatory interpretation without biopsy would risk **understaging** the patient's lung cancer, as the node meets the metabolic criteria for malignancy.

Q: How does 68Ga-DOTATATE molecular imaging differ from FDG-PET in mechanism of tumor detection?

It binds to somatostatin receptors. ***It binds to somatostatin receptors*** - **68Ga-DOTATATE** is a radiolabeled somatostatin analogue that specifically targets cells overexpressing **somatostatin receptors (SSTR)**, particularly subtype **SSTR2**. - This receptor-ligand binding allows for highly specific imaging of **neuroendocrine tumors (NETs)**, which is fundamentally different from metabolic pathways. *It targets metabolic activity* - This describes the mechanism of **18F-FDG PET**, which relies on **glucose metabolism** and the upregulation of **GLUT transporters** in malignant cells. - While effective for aggressive cancers, many low-grade neuroendocrine tumors have low metabolic rates and may be **FDG-negative**. *It measures blood flow* - Measuring blood flow is characteristic of certain **perfusion scans** or dynamic contrast-enhanced imaging, not the molecular targeting of DOTATATE. - Radiopharmaceuticals like **15O-water** or certain technetium-based agents are used for perfusion studies rather than receptor-specific mapping. *It detects DNA synthesis* - Agents that detect DNA synthesis, such as **18F-FLT**, target the enzyme **thymidine kinase-1** to visualize cellular proliferation. - While provide information on tumor growth, this is distinct from the **somatostatin receptor expression** targeted by **68Ga-DOTATATE**.

Q: What is the underlying principle behind FDG uptake in malignant cells during PET imaging?

Warburg effect and increased glycolysis. ***Warburg effect and increased glycolysis*** - Malignant cells exhibit the **Warburg effect**, which is characterized by high rates of **glycolysis** and glucose uptake even in the presence of oxygen. - **FDG (Fluorodeoxyglucose)** is a glucose analogue that is transported into cells by **GLUT transporters** and phosphorylated, but it remains trapped as it cannot undergo further metabolism. *Increased fatty acid metabolism* - While some cancers may utilize fatty acids, PET imaging with FDG specifically targets the **glucose metabolic pathway**, not lipid metabolism. - Fatty acid imaging typically requires different radiopharmaceuticals, such as **11C-acetate** or **18F-FCHP**. *Increased DNA synthesis* - Increased DNA synthesis is a hallmark of cellular proliferation but is not the mechanism detected by **FDG-PET scans**. - Radiotracers like **18F-FLT (fluorothymidine)** are used to measure proliferation and DNA synthesis rather than glucose consumption. *Enhanced protein synthesis* - Enhanced protein synthesis reflects the **anabolic state** of a tumor but does not explain the accumulation of glucose analogues. - Amino acid analogues, such as **11C-methionine** or **18F-FET**, are specifically used to image protein synthesis and amino acid transport in oncology.

Q: What is the physical half-life of Fluorine-18 used in PET imaging?

110 minutes. ***110 minutes*** - **Fluorine-18 (F-18)** has a physical half-life of approximately **109.8 minutes**, making it ideal for clinical PET imaging. - This duration is long enough to allow for **radiopharmaceutical synthesis** and distribution, yet short enough to limit the patient's **radiation dose**. *24 hours* - This is much longer than the half-life of common **PET isotopes** and would lead to excessive, unnecessary radiation exposure. - **Indium-111**, used in SPECT imaging, has a longer half-life (approx. **2.8 days**), but is not F-18. *20 minutes* - This describes the half-life of **Carbon-11**, another positron emitter used in PET research. - Isotopes with a **20-minute half-life** require an **on-site cyclotron** because they decay too rapidly for transport between facilities. *6 hours* - This is the physical half-life of **Technetium-99m**, the most widely used isotope in **diagnostic nuclear medicine (SPECT)**. - While **6 hours** is convenient for logistics, it is not associated with the positron emission decay of **Fluorine-18**.

Q: Which radiotracer is most commonly used for FDG-PET imaging in oncology?

18F-Fluorodeoxyglucose. ***18F-Fluorodeoxyglucose*** - **18F-FDG** is a glucose analogue that is taken up by cells via **GLUT transporters** and phosphorylated, but cannot be further metabolized, leading to **metabolic trapping**. - It is the gold standard for oncology PET imaging because malignant cells exhibit **Warburg effect**, showing significantly increased **glucose metabolism** compared to normal tissues. *68Ga-DOTATATE* - This is a specialized radiotracer used specifically for imaging **neuroendocrine tumors** that express **somatostatin receptors**. - It is not used for general oncologic screening as it does not rely on the high glucose demands of typical carcinomas. *99mTc-Sestamibi* - This is primarily used in **SPECT imaging**, not PET, for applications such as **myocardial perfusion** imaging and checking **parathyroid adenomas**. - Unlike FDG, it is a lipophilic cation that localizes in **mitochondria** rather than tracking glucose consumption. *11C-Methionine* - This is an **amino acid tracer** used mainly in **neuro-oncology** to differentiate brain tumor recurrence from radiation necrosis. - Its use is limited in routine clinical practice due to the very short **half-life of Carbon-11** (approximately 20 minutes), requiring an on-site cyclotron.

A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?

In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?

A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?

A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?

A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?

A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?

How does 68Ga-DOTATATE molecular imaging differ from FDG-PET in mechanism of tumor detection?

What is the underlying principle behind FDG uptake in malignant cells during PET imaging?

What is the physical half-life of Fluorine-18 used in PET imaging?

Q10

Which radiotracer is most commonly used for FDG-PET imaging in oncology?

Molecular Imaging Indian Medical PG Practice Questions and MCQs

Question 1: A research team is developing a new radiotracer for imaging hypoxia in tumors. They need to select between 18F-labeled and 64Cu-labeled versions of the same molecule. Considering half-lives (18F: 110 min, 64Cu: 12.7 hours), positron ranges, and clinical applicability, which choice and rationale is most appropriate?

A. 64Cu for longer imaging window despite inferior image quality
B. 64Cu because shorter positron range improves resolution
C. 18F for better spatial resolution despite requiring on-site cyclotron (Correct Answer)
D. 18F because longer half-life allows delayed imaging

Explanation: ***18F for better spatial resolution despite requiring on-site cyclotron*** - **18F** has a shorter **positron range** compared to **64Cu**, which minimizes the distance the positron travels before annihilation, leading to superior **spatial resolution**. - While it necessitates proximity to a **cyclotron** due to a 110-minute half-life, this timeframe is sufficient for most **hypoxia imaging** tracers to reach a high **target-to-background ratio**. *64Cu for longer imaging window despite inferior image quality* - **64Cu** provides a longer imaging window due to its **12.7-hour half-life**, but its longer **positron range** leads to increased **blurring** and poorer resolution. - For diagnostic **tumor hypoxia**, the extra-long window is often unnecessary and leads to a higher **absorbed radiation dose** for the patient. *64Cu because shorter positron range improves resolution* - This statement is factually incorrect as **64Cu** actually has a significantly longer **effective positron range** than **18F**. - Higher **energy positrons** travel further in tissue, which degrades the **image quality** by misplacing the site of annihilation relative to the source. *18F because longer half-life allows delayed imaging* - This is incorrect as **18F** has a much shorter half-life (**110 minutes**) compared to the **12.7 hours** of **64Cu**. - The shorter half-life of **18F** prevents very late delayed imaging but helps in keeping the total **patient radiation exposure** lower.

Question 2: In designing a clinical protocol for PSMA PET imaging in prostate cancer, which combination of factors would provide optimal image quality while minimizing radiation exposure?

A. 18F-PSMA with 4 hour delayed imaging
B. 68Ga-PSMA with 3 hour uptake time without furosemide
C. 68Ga-PSMA with 1 hour uptake time and furosemide administration (Correct Answer)
D. 18F-PSMA with 30 minutes uptake time and forced hydration

Explanation: ***68Ga-PSMA with 1 hour uptake time and furosemide administration*** - An **uptake time of 60 minutes** is the standard for **68Ga-PSMA**, providing an optimal **target-to-background ratio** (TBR) while maintaining efficient clinical workflow. - The administration of **furosemide** (a loop diuretic) promotes **urinary washout** of the tracer, reducing interfering **bladder activity** and lowering the radiation dose to the urinary tract. *18F-PSMA with 4 hour delayed imaging* - While **18F-labeled tracers** have a longer half-life, a 4-hour delay is excessive and leads to significant **decay of activity**, potentially requiring higher initial doses and increasing **radiation exposure**. - Such long delays are not practical for routine clinical protocols and do not provide a significant clinical advantage over standard 1-2 hour imaging for most **PSMA** ligands. *68Ga-PSMA with 3 hour uptake time without furosemide* - **68Ga** has a short physical half-life (68 minutes), so a 3-hour wait significantly reduces the **count rate**, leading to poor **image quality** due to increased noise. - Omitting **furosemide** results in high tracer concentration in the **bladder**, which can obscure local recurrence in the **prostate bed** or nearby pelvic lymph nodes via **halo artifacts**. *18F-PSMA with 30 minutes uptake time and forced hydration* - A **30-minute uptake time** is generally insufficient for optimal **tracer internalization** into prostate cancer cells, resulting in a lower **tumor-to-background ratio**. - Although **forced hydration** helps, it is less effective than **furosemide** at rapidly clearing the high-intensity tracer from the **distal ureters** and bladder during the peak imaging window.

Question 3: A patient with treated breast cancer shows a liver lesion on CT. FDG-PET shows SUVmax of 2.8 in the lesion. Follow-up scan after 3 months shows increase in size but SUVmax decreased to 1.9. What is the most likely explanation?

A. Progressive disease requiring treatment escalation
B. Treatment-induced necrosis with favorable prognosis (Correct Answer)
C. Flare phenomenon indicating treatment response
D. Infection complicating the metastasis

Explanation: ***Treatment-induced necrosis with favorable prognosis*** - A decrease in **SUVmax** indicates a reduction in **metabolic activity** and viable tumor cells, even if the physical dimensions of the lesion increase. - The increase in size is often due to **necrosis, edema, or inflammation** following successful therapy, representing a favorable response to treatment rather than failure. *Progressive disease requiring treatment escalation* - Progressive disease typically presents with an **increase in both size and SUVmax**, reflecting active metabolic growth of the tumor. - Relying solely on **CT size measurements** (like RECIST criteria) can be misleading when PET shows a significant drop in **glucose metabolism**. *Flare phenomenon indicating treatment response* - The **flare phenomenon** usually refers to a transient *increase* in tracer uptake (SUVmax) shortly after starting treatment (e.g., bone flare in breast cancer patients). - In this scenario, the activity **decreased over 3 months**, which is more consistent with a sustained metabolic response than a metabolic flare. *Infection complicating the metastasis* - An active infection or inflammatory process would typically lead to an **increase in SUVmax** due to high metabolic activity in activated white blood cells. - There is no clinical information provided to suggest systemic **fever or local infection**, and the metabolic trend (decreasing SUV) contradicts an inflammatory spike.

Question 4: A 58-year-old woman with gastrinoma undergoes both FDG-PET and 68Ga-DOTATATE PET scans. FDG-PET shows minimal uptake (SUVmax 2.1) while DOTATATE scan shows intense uptake (SUVmax 45). What does this pattern indicate about tumor biology?

A. High grade aggressive tumor
B. Well-differentiated slow-growing tumor (Correct Answer)
C. Necrotic tumor with inflammation
D. False positive DOTATATE scan

Explanation: ***Well-differentiated slow-growing tumor*** - High **DOTATATE uptake** indicates dense expression of **somatostatin receptors (SSTRs)**, which is a hallmark of well-differentiated neuroendocrine tumors. - Low **FDG uptake** (low SUVmax) reflects a low rate of glucose metabolism, signifying a **low-grade (G1/G2)** tumor with a slow proliferation rate. *High grade aggressive tumor* - Aggressive, high-grade neuroendocrine carcinomas (G3) typically show high **FDG avidity** because they rely heavily on glycolysis for energy. - These tumors often lose their **somatostatin receptor expression**, leading to low or absent uptake on a **DOTATATE scan**. *Necrotic tumor with inflammation* - **Necrosis** generally presents as a photopenic (cold) area in the center of a lesion on PET imaging, not intense DOTATATE uptake. - **Inflammation** would typically result in increased **FDG uptake** due to high metabolic activity in activated leukocytes, rather than isolated high DOTATATE avidity. *False positive DOTATATE scan* - Intense uptake with an **SUVmax of 45** is highly specific for SSTR-rich tissues and is considered diagnostic for neuroendocrine pathology in this clinical context. - A **gastrinoma** is a known neuroendocrine tumor (NET) that consistently expresses these receptors, making a false positive highly unlikely.

Question 5: A 45-year-old diabetic patient presents for FDG-PET scan for lymphoma staging. Blood glucose is 220 mg/dL. What is the most appropriate management before proceeding with imaging?

A. Administer insulin and delay scan until glucose <150 mg/dL (Correct Answer)
B. Double the FDG dose to compensate
C. Cancel scan and reschedule after glucose control
D. Proceed immediately with scanning

Explanation: ***Administer insulin and delay scan until glucose <150 mg/dL*** - **Hyperglycemia** causes competitive inhibition of **FDG uptake** in tumor cells, as glucose and FDG compete for the same **GLUT transporters**. - Administering insulin lowers blood glucose to an acceptable range (ideally **<150 mg/dL**) to ensure optimal **diagnostic accuracy** and image quality, though scanning should occur at least 2 hours after insulin administration to avoid muscle uptake. *Double the FDG dose to compensate* - Increasing the **FDG dose** does not bypass the competitive inhibition caused by serum glucose and will only increase **radiation exposure** unnecessarily. - High blood sugar levels will still prioritize **native glucose** over FDG into cells, resulting in a poor **signal-to-noise ratio**. *Cancel scan and reschedule after glucose control* - While long-term control is ideal, acute management with **short-acting insulin** allows the scan to proceed on the same day once levels fall below the threshold. - Rescheduling is only necessary if the patient's **blood glucose** remains persistently high and unresponsive to immediate clinical intervention. *Proceed immediately with scanning* - Scanning with a glucose level of **220 mg/dL** leads to poor image quality and potential **false-negative** results due to diminished tracer uptake in the lymphoma. - Elevated **endogenous glucose** saturates the receptors, preventing the radioactive tracer from adequately labeling the **metabolically active** tumor sites.

Question 6: A 65-year-old man with known lung cancer undergoes FDG-PET scan. The scan shows intense FDG uptake (SUVmax 8.5) in the primary lung mass and a 1.2 cm mediastinal lymph node with SUVmax 4.2. What is the most appropriate interpretation?

A. Both primary and nodal metastasis (Correct Answer)
B. Primary tumor with false positive node
C. Dual primary malignancies
D. Primary tumor only, node is inflammatory

Explanation: ***Both primary and nodal metastasis*** - In lung cancer staging, a **Standardized Uptake Value (SUVmax)** greater than 2.5 in mediastinal lymph nodes is highly suspicious for **metastatic involvement**. - The node's SUVmax of 4.2 relative to the primary tumor's high uptake (8.5) strongly indicates **metabolically active disease** at both the primary and nodal sites. *Primary tumor with false positive node* - **False positives** on PET often occur due to granulomatous disease or infection, but an SUVmax of 4.2 in a known cancer context is more likely **metastatic**. - Without history of **sarcoidosis** or active infection, the metabolic activity in the lymphatic basin of the primary tumor is considered malignant until proven otherwise. *Dual primary malignancies* - Two separate primary malignancies would typically involve different anatomical sites or different **histological features**, rather than a primary and its draining node. - The presence of a mediastinal node in a patient with a known lung mass is the classic presentation of **regional spread** (N staging), not a second primary site. *Primary tumor only, node is inflammatory* - While inflammation can cause **FDG avidity**, an SUVmax of 4.2 is significantly high and less typical for purely reactive or **incidental inflammatory** nodes. - Relying on an inflammatory interpretation without biopsy would risk **understaging** the patient's lung cancer, as the node meets the metabolic criteria for malignancy.

Question 7: How does 68Ga-DOTATATE molecular imaging differ from FDG-PET in mechanism of tumor detection?

A. It targets metabolic activity
B. It binds to somatostatin receptors (Correct Answer)
C. It measures blood flow
D. It detects DNA synthesis

Explanation: ***It binds to somatostatin receptors*** - **68Ga-DOTATATE** is a radiolabeled somatostatin analogue that specifically targets cells overexpressing **somatostatin receptors (SSTR)**, particularly subtype **SSTR2**. - This receptor-ligand binding allows for highly specific imaging of **neuroendocrine tumors (NETs)**, which is fundamentally different from metabolic pathways. *It targets metabolic activity* - This describes the mechanism of **18F-FDG PET**, which relies on **glucose metabolism** and the upregulation of **GLUT transporters** in malignant cells. - While effective for aggressive cancers, many low-grade neuroendocrine tumors have low metabolic rates and may be **FDG-negative**. *It measures blood flow* - Measuring blood flow is characteristic of certain **perfusion scans** or dynamic contrast-enhanced imaging, not the molecular targeting of DOTATATE. - Radiopharmaceuticals like **15O-water** or certain technetium-based agents are used for perfusion studies rather than receptor-specific mapping. *It detects DNA synthesis* - Agents that detect DNA synthesis, such as **18F-FLT**, target the enzyme **thymidine kinase-1** to visualize cellular proliferation. - While provide information on tumor growth, this is distinct from the **somatostatin receptor expression** targeted by **68Ga-DOTATATE**.

Question 8: What is the underlying principle behind FDG uptake in malignant cells during PET imaging?

A. Warburg effect and increased glycolysis (Correct Answer)
B. Increased fatty acid metabolism
C. Increased DNA synthesis
D. Enhanced protein synthesis

Explanation: ***Warburg effect and increased glycolysis*** - Malignant cells exhibit the **Warburg effect**, which is characterized by high rates of **glycolysis** and glucose uptake even in the presence of oxygen. - **FDG (Fluorodeoxyglucose)** is a glucose analogue that is transported into cells by **GLUT transporters** and phosphorylated, but it remains trapped as it cannot undergo further metabolism. *Increased fatty acid metabolism* - While some cancers may utilize fatty acids, PET imaging with FDG specifically targets the **glucose metabolic pathway**, not lipid metabolism. - Fatty acid imaging typically requires different radiopharmaceuticals, such as **11C-acetate** or **18F-FCHP**. *Increased DNA synthesis* - Increased DNA synthesis is a hallmark of cellular proliferation but is not the mechanism detected by **FDG-PET scans**. - Radiotracers like **18F-FLT (fluorothymidine)** are used to measure proliferation and DNA synthesis rather than glucose consumption. *Enhanced protein synthesis* - Enhanced protein synthesis reflects the **anabolic state** of a tumor but does not explain the accumulation of glucose analogues. - Amino acid analogues, such as **11C-methionine** or **18F-FET**, are specifically used to image protein synthesis and amino acid transport in oncology.

Question 9: What is the physical half-life of Fluorine-18 used in PET imaging?

A. 24 hours
B. 110 minutes (Correct Answer)
C. 20 minutes
D. 6 hours

Explanation: ***110 minutes*** - **Fluorine-18 (F-18)** has a physical half-life of approximately **109.8 minutes**, making it ideal for clinical PET imaging. - This duration is long enough to allow for **radiopharmaceutical synthesis** and distribution, yet short enough to limit the patient's **radiation dose**. *24 hours* - This is much longer than the half-life of common **PET isotopes** and would lead to excessive, unnecessary radiation exposure. - **Indium-111**, used in SPECT imaging, has a longer half-life (approx. **2.8 days**), but is not F-18. *20 minutes* - This describes the half-life of **Carbon-11**, another positron emitter used in PET research. - Isotopes with a **20-minute half-life** require an **on-site cyclotron** because they decay too rapidly for transport between facilities. *6 hours* - This is the physical half-life of **Technetium-99m**, the most widely used isotope in **diagnostic nuclear medicine (SPECT)**. - While **6 hours** is convenient for logistics, it is not associated with the positron emission decay of **Fluorine-18**.

Question 10: Which radiotracer is most commonly used for FDG-PET imaging in oncology?

A. 18F-Fluorodeoxyglucose (Correct Answer)
B. 68Ga-DOTATATE
C. 99mTc-Sestamibi
D. 11C-Methionine

Explanation: ***18F-Fluorodeoxyglucose*** - **18F-FDG** is a glucose analogue that is taken up by cells via **GLUT transporters** and phosphorylated, but cannot be further metabolized, leading to **metabolic trapping**. - It is the gold standard for oncology PET imaging because malignant cells exhibit **Warburg effect**, showing significantly increased **glucose metabolism** compared to normal tissues. *68Ga-DOTATATE* - This is a specialized radiotracer used specifically for imaging **neuroendocrine tumors** that express **somatostatin receptors**. - It is not used for general oncologic screening as it does not rely on the high glucose demands of typical carcinomas. *99mTc-Sestamibi* - This is primarily used in **SPECT imaging**, not PET, for applications such as **myocardial perfusion** imaging and checking **parathyroid adenomas**. - Unlike FDG, it is a lipophilic cation that localizes in **mitochondria** rather than tracking glucose consumption. *11C-Methionine* - This is an **amino acid tracer** used mainly in **neuro-oncology** to differentiate brain tumor recurrence from radiation necrosis. - Its use is limited in routine clinical practice due to the very short **half-life of Carbon-11** (approximately 20 minutes), requiring an on-site cyclotron.

Question 11: Positron emission tomographic (PET) scanning is useful in the evaluation of which of the following conditions?

A. Mycotic aortic aneurysm (Correct Answer)
B. Solitary pulmonary nodules
C. Staging lung cancer
D. Lymph node involvement by malignancy

Explanation: **Explanation:** The correct answer is **A. Mycotic aortic aneurysm**. While PET scanning is traditionally associated with oncology, its role in detecting **vascular inflammation and infection** is a high-yield concept for NEET-PG. **1. Why Mycotic Aortic Aneurysm is the Correct Answer:** A mycotic aneurysm is an infected arterial wall. PET/CT using **18F-FDG** (Fluorodeoxyglucose) is highly sensitive for this condition because activated inflammatory cells (neutrophils and macrophages) at the site of infection have a significantly high metabolic rate and glucose requirement. FDG-PET can detect these "hot spots" of infection even before structural changes are visible on a conventional CT, making it superior for diagnosing infected prostheses and vascular grafts. **2. Analysis of Other Options:** * **B, C, and D (Solitary pulmonary nodules, Staging lung cancer, Lymph node involvement):** While PET is indeed used for these conditions, they represent the *standard* oncological applications of the technology. In the context of this specific question (often derived from recent clinical updates or Harrison’s/Bailey’s), the focus is on the **emerging or specific utility** in vascular infections where conventional imaging might be equivocal. *Note: If this were a "Multiple Select" question, all would be correct; however, in a single-best-response format, the focus is on the specific inflammatory application.* **Clinical Pearls for NEET-PG:** * **Mechanism:** FDG is a glucose analog; it is taken up by cells via GLUT transporters and phosphorylated but cannot be further metabolized, leading to "metabolic trapping." * **False Positives:** PET can be positive in non-malignant conditions like **Tuberculosis, Sarcoidosis, and Fungal infections** (due to high metabolic activity of granulomas). * **Brain Imaging:** PET is the gold standard for differentiating **Radiation Necrosis** (cold/low uptake) from **Tumor Recurrence** (hot/high uptake). * **Myocardial Viability:** FDG-PET is the "Gold Standard" for identifying hibernating myocardium.

Question 12: Which of the following imaging modalities is used to differentiate tumor recurrence from radiation necrosis?

A. PET scan (Correct Answer)
B. MRI
C. 3D CT
D. USG

Explanation: **Explanation:** The differentiation between **tumor recurrence** and **radiation necrosis** is a classic clinical challenge because both entities often appear identical on conventional structural imaging (like CT or MRI), showing contrast enhancement and perilesional edema. **1. Why PET Scan is the Correct Answer:** The distinction relies on **metabolic activity** rather than anatomy. * **Tumor Recurrence:** Malignant cells are hypermetabolic and demonstrate high uptake of radiopharmaceuticals like **18F-FDG** (Fluorodeoxyglucose) or amino acid tracers (e.g., 11C-Methionine). * **Radiation Necrosis:** This represents dead tissue and vascular injury; it is metabolically inactive (hypometabolic) and shows little to no tracer uptake. Therefore, PET imaging provides the functional data necessary to distinguish "hot" viable tumor from "cold" necrotic tissue. **2. Why Other Options are Incorrect:** * **MRI:** While advanced sequences like MR Spectroscopy (showing high Choline/NAA ratios) can help, standard MRI often fails because both necrosis and recurrence cause blood-brain barrier breakdown and enhancement. * **3D CT:** CT provides excellent structural detail of bone and acute hemorrhage but lacks the metabolic sensitivity to differentiate viable tumor cells from post-radiation changes. * **USG:** Ultrasound has no role in evaluating deep-seated brain tumors or post-radiation changes due to the inability of sound waves to penetrate the adult cranium. **Clinical Pearls for NEET-PG:** * **Gold Standard:** While PET is the preferred functional imaging, **MR Spectroscopy (MRS)** is the most common "advanced MRI" alternative mentioned in exams. * **Tracer of Choice:** In the brain, **18F-FET** or **11C-Methionine** are often superior to FDG because the brain has high baseline glucose uptake, which can mask tumors. * **Hot vs. Cold:** Remember: **Recurrence = Hot (Hypermetabolic)**; **Necrosis = Cold (Hypometabolic).**

Question 13: What isotope is commonly used in PET scans?

A. Phosphorus-32
B. 18-fluoro-deoxyglucose (Correct Answer)
C. Iridium-77
D. Radium-226

Explanation: **Explanation:** **18-Fluoro-deoxyglucose (18-FDG)** is the most widely used radiopharmaceutical in Positron Emission Tomography (PET). The underlying principle is **metabolic imaging**. 18-FDG is a glucose analog; it is taken up by cells via GLUT transporters and phosphorylated by hexokinase. However, unlike normal glucose, it cannot undergo further glycolysis and becomes "trapped" within the cell (**metabolic trapping**). Since malignant cells have high metabolic rates and increased GLUT-1 expression, they accumulate higher concentrations of 18-FDG, appearing as "hot spots" on the scan. **Analysis of Incorrect Options:** * **Phosphorus-32:** A pure beta-emitter used primarily for therapeutic purposes, such as treating Polycythemia Vera or for intracavitary treatment of malignant effusions. * **Iridium-192 (Note: Iridium-77 is not a standard medical isotope):** Commonly used in **Brachytherapy** (e.g., breast or prostate cancer) as a source for high-dose-rate (HDR) radiation. * **Radium-226:** Historically used in brachytherapy (pioneered by Marie Curie), but largely replaced by safer isotopes like Cesium-137 due to its long half-life and daughter product (Radon gas) risks. **Clinical Pearls for NEET-PG:** * **Physics:** PET relies on **Annihilation Radiation**. A positron emitted by the isotope meets an electron, producing two 511 keV photons traveling in opposite directions (180°). * **Half-life:** The half-life of Fluorine-18 is approximately **110 minutes**. * **Preparation:** Patients must be **fasting (4–6 hours)** and have controlled blood glucose levels (<200 mg/dL) to minimize competition between endogenous glucose and 18-FDG. * **False Positives:** FDG is not cancer-specific; it also accumulates in areas of active **inflammation and infection** (e.g., Tuberculosis).

Question 14: What is meant by PET scan?

A. Positive Emission Tomography
B. Positron Emission Tomography (Correct Answer)
C. Positron Energy Tomography
D. Positive Energy Tomography

Explanation: **Explanation:** **Positron Emission Tomography (PET)** is a functional nuclear medicine imaging technique that visualizes metabolic processes in the body. The correct answer is **Option B** because the technology relies on the detection of pairs of gamma rays emitted indirectly by a **positron-emitting radionuclide** (tracer). **Why the correct answer is right:** When a radiopharmaceutical (like FDG) is injected, the radioisotope undergoes beta-plus decay, emitting a **positron** (an anti-matter particle). This positron travels a short distance before colliding with an electron, resulting in an **annihilation event**. This event produces two 511 keV photons (gamma rays) traveling in opposite directions, which are detected by the PET scanner to create a 3D image of metabolic activity. **Why the incorrect options are wrong:** * **Option A & D:** "Positive" is a common distractor; while positrons have a positive charge, the "P" specifically stands for the particle name (Positron). * **Option C & D:** "Energy" is incorrect as the "E" stands for **Emission**, referring to the release of radiation from within the patient's body (unlike X-rays/CT where radiation is transmitted through the patient). **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Tracer:** **18F-FDG** (Fluorodeoxyglucose), a glucose analog. It is taken up by cells via GLUT transporters and trapped by phosphorylation. * **Clinical Use:** Primarily used for **oncology** (staging and treatment response), **cardiology** (myocardial viability), and **neurology** (epilepsy and Alzheimer’s). * **Key Physics Fact:** The annihilation photons always have an energy of **511 keV**. * **Physiological Uptake:** Normal "hot spots" include the brain, heart, kidneys, and urinary bladder.

Question 15: Which of the following imaging modalities is most appropriate for initial evaluation of suspected acute appendicitis in a young adult patient?

A. Ultrasound (Correct Answer)
B. CT scan (Contrast-enhanced)
C. Plain radiography (X-ray)
D. MRI

Explanation: ***Ultrasound*** - **First-line imaging modality** for suspected acute appendicitis in young adults, especially in children, pregnant women, and young females - **Advantages:** No ionizing radiation, readily available, cost-effective, can be performed at bedside - **High specificity** (>90%) when positive findings are present - **Graded compression technique** helps visualize the appendix and assess for periappendiceal inflammation - **Limitations:** Operator-dependent, may be difficult in obese patients or with overlying bowel gas *CT scan (Contrast-enhanced)* - **Most sensitive imaging modality** (sensitivity >95%) for acute appendicitis - Considered when ultrasound is inconclusive or technically difficult - **Gold standard** in adults, especially in obese patients - Provides excellent visualization of the appendix and complications (perforation, abscess) - However, involves **ionizing radiation**, making it less ideal as first-line in young patients *MRI* - **Preferred in pregnant women** when ultrasound is inconclusive - No ionizing radiation exposure - High accuracy but **limited availability**, longer scan time, and higher cost - Not typically used as first-line imaging in non-pregnant young adults *Plain radiography (X-ray)* - **Limited role** in diagnosing acute appendicitis - Non-specific findings; may show fecalith, loss of psoas shadow, or signs of perforation - Cannot reliably visualize the appendix - **Not recommended** as initial imaging for suspected appendicitis

Question 16: The most appropriate first-line imaging modality to detect adrenal metastasis due to bronchogenic carcinoma is:

A. PET scan
B. MRI of the abdomen
C. Adrenal radionuclide scan
D. Contrast Enhanced CT abdomen (Correct Answer)

Explanation: **Contrast Enhanced CT abdomen** - **Contrast-enhanced CT abdomen** is generally considered the most sensitive and cost-effective imaging modality for detecting **adrenal metastases**. - It allows for detailed visualization of adrenal gland morphology, including size, shape, and enhancement patterns, which can help differentiate benign from malignant lesions. *PET scan* - While **PET (Positron Emission Tomography) scans** are highly sensitive for detecting metabolically active metastatic disease, they are often used as a secondary imaging modality to characterize indeterminate lesions found on CT or MRI. - **PET scans** can have false positives in benign adrenal tumors (e.g., adenomas rich in fat) and are less readily available or higher in cost for initial screening compared to CT. *MRI of the abdomen* - **MRI of the abdomen** can be very useful for further characterization of adrenal masses, especially for distinguishing between lipid-rich adenomas and metastases. - However, for initial detection, especially in the context of screening for distant metastases from bronchogenic carcinoma, **CT is generally preferred due to its wider availability, speed, and lower cost**. *Adrenal radionuclide scan* - **Adrenal radionuclide scans** (e.g., using MIBG or iodocholesterol) are primarily used for functional imaging of adrenal glands, typically to detect specific types of tumors like pheochromocytomas or aldosteronomas. - These scans are **not sensitive for detecting adrenal metastases** from bronchogenic carcinoma, as the metastatic lesions do not typically exhibit the specific uptake patterns targeted by these radiotracers.

Practice by Chapter

Principles of Molecular Imaging

Practice Questions

Radiopharmaceuticals for Molecular Imaging

Practice Questions

PET Radiochemistry

Practice Questions

Molecular Imaging in Oncology

Practice Questions

Molecular Imaging in Cardiology

Practice Questions

Molecular Imaging in Neurology

Practice Questions

Molecular Imaging in Inflammation and Infection

Practice Questions

Reporter Gene Imaging

Practice Questions

Cell Tracking and Imaging

Practice Questions

Nanoparticles in Molecular Imaging

Practice Questions

Theranostics

Practice Questions

Future Directions in Molecular Imaging

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free